These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 26093599)

  • 1. [The stabilizing effect of dehydroepiandrosterone on clinical parameters of metabolic syndrome in patients with schizophrenia treated with olanzapine - a randomized, double-blind trial].
    Holka-Pokorska JA; Radzio R; Jarema M; Wichniak A
    Psychiatr Pol; 2015; 49(2):363-76. PubMed ID: 26093599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study.
    Smith RC; Lindenmayer JP; Hu Q; Kelly E; Viviano TF; Cornwell J; Vaidhyanathaswamy S; Marcovina S; Davis JM
    Schizophr Res; 2010 Jul; 120(1-3):204-9. PubMed ID: 20457512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, 12-week study of the effects of extended-release paliperidone (paliperidone ER) and olanzapine on metabolic profile, weight, insulin resistance, and β-cell function in schizophrenic patients.
    Hu S; Yao M; Peterson BS; Xu D; Hu J; Tang J; Fan B; Liao Z; Yuan T; Li Y; Yue W; Wei N; Zhou W; Huang M; Xu Y
    Psychopharmacology (Berl); 2013 Nov; 230(1):3-13. PubMed ID: 23559220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjunctive telmisartan treatment on body metabolism in clozapine or olanzapine treated patients with schizophrenia: a randomized, double blind, placebo controlled trial.
    Fan X; Copeland P; Nawras S; Harrington A; Freudenreich O; Goff DC; Henderson DC
    Psychopharmacology (Berl); 2019 Jun; 236(6):1949-1957. PubMed ID: 30747254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of clinical symptomatology, extrapyramidal symptoms and neurocognitive dysfunction following dehydroepiandrosterone (DHEA) administration in olanzapine treated schizophrenia patients: a randomized, double-blind placebo controlled trial.
    Strous RD; Stryjer R; Maayan R; Gal G; Viglin D; Katz E; Eisner D; Weizman A
    Psychoneuroendocrinology; 2007 Feb; 32(2):96-105. PubMed ID: 17208382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol.
    Krakowski M; Czobor P; Citrome L
    Schizophr Res; 2009 May; 110(1-3):95-102. PubMed ID: 19269139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effects of ziprasidone and olanzapine on glucose and lipid metabolism in first-episode schizophrenia].
    Shao P; Ou J; Wu R; Fang M; Chen H; Xu Y; Zhao J
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 Apr; 38(4):365-9. PubMed ID: 23645236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of pioglitazone on metabolic abnormalities, psychopathology, and cognitive function in schizophrenic patients treated with antipsychotic medication: a randomized double-blind study.
    Smith RC; Jin H; Li C; Bark N; Shekhar A; Dwivedi S; Mortiere C; Lohr J; Hu Q; Davis JM
    Schizophr Res; 2013 Jan; 143(1):18-24. PubMed ID: 23200554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial.
    Baptista T; Martínez J; Lacruz A; Rangel N; Beaulieu S; Serrano A; Arapé Y; Martinez M; de Mendoza S; Teneud L; Hernández L
    Can J Psychiatry; 2006 Mar; 51(3):192-6. PubMed ID: 16618011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: a prospective, randomized, controlled trial.
    Schreiner A; Niehaus D; Shuriquie NA; Aadamsoo K; Korcsog P; Salinas R; Theodoropoulou P; Fernández LG; Uçok A; Tessier C; Bergmans P; Hoeben D
    J Clin Psychopharmacol; 2012 Aug; 32(4):449-57. PubMed ID: 22722501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized controlled trial of the effect of sublingual orally disintegrating olanzapine versus oral olanzapine on body mass index: the PLATYPUS Study.
    Karagianis J; Grossman L; Landry J; Reed VA; de Haan L; Maguire GA; Hoffmann VP; Milev R
    Schizophr Res; 2009 Aug; 113(1):41-8. PubMed ID: 19535229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial.
    Narula PK; Rehan HS; Unni KE; Gupta N
    Schizophr Res; 2010 May; 118(1-3):218-23. PubMed ID: 20207521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study.
    Wu RR; Zhao JP; Guo XF; He YQ; Fang MS; Guo WB; Chen JD; Li LH
    Am J Psychiatry; 2008 Mar; 165(3):352-8. PubMed ID: 18245179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effects of olanzapine and risperidone on plasma adiponectin levels over time: results from a 3-month prospective open-label study.
    Wampers M; Hanssens L; van Winkel R; Heald A; Collette J; Peuskens J; Reginster JY; Scheen A; De Hert M
    Eur Neuropsychopharmacol; 2012 Jan; 22(1):17-26. PubMed ID: 21511441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of long-term metabolic effects of olanzapine and risperidone treatment from baseline body mass index in schizophrenia and bipolar disorder.
    Bobo WV; Bonaccorso S; Jayathilake K; Meltzer HY
    Psychiatry Res; 2011 Sep; 189(2):200-7. PubMed ID: 21802150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial.
    Kryzhanovskaya L; Schulz SC; McDougle C; Frazier J; Dittmann R; Robertson-Plouch C; Bauer T; Xu W; Wang W; Carlson J; Tohen M
    J Am Acad Child Adolesc Psychiatry; 2009 Jan; 48(1):60-70. PubMed ID: 19057413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia.
    Kinon BJ; Stauffer VL; Kollack-Walker S; Chen L; Sniadecki J
    J Clin Psychopharmacol; 2008 Dec; 28(6):601-7. PubMed ID: 19011427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sex difference in effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia.
    Wu RR; Zhao JP; Zhai JG; Guo XF; Guo WB
    J Clin Psychopharmacol; 2007 Aug; 27(4):374-9. PubMed ID: 17632222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population.
    Perez-Iglesias R; Mata I; Pelayo-Teran JM; Amado JA; Garcia-Unzueta MT; Berja A; Martinez-Garcia O; Vazquez-Barquero JL; Crespo-Facorro B
    Schizophr Res; 2009 Feb; 107(2-3):115-21. PubMed ID: 18993033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of reboxetine co-administration with olanzapine on metabolic and endocrine profile in schizophrenia patients.
    Amrami-Weizman A; Maayan R; Gil-Ad I; Pashinian A; Fuchs C; Kotler M; Poyurovsky M
    Psychopharmacology (Berl); 2013 Nov; 230(1):23-7. PubMed ID: 23828160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.